Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of emactuzumab versus placebo in tenosynovial giant cell tumour
2023-510422-32-00Phase 3Authorised
- Sponsor
- SynOx Therapeutics
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of emactuzumab in tenosynovial giant cell tumor (TGCT) (3 arms), sponsored by SynOx Therapeutics. Primary endpoint: Objective response rate by RECIST v1.1 at 6 months. Planned start Sep 2024; status: authorised.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on 2023-510422-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510422-32-00.